NVCT (STOCKS)
Nuvectis Pharma, Inc. Common Stock
$8.800000
+0.020000 (+0.23%)
Prev close: $8.780000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Ronald E. Bentsur
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $226.18M
- Employees
- 13
- P/E (TTM)
- -6.85
- P/B (TTM)
- 12.24
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.33 | $-0.25 | -0.0775 | -30.69% |
|
Jun 2025 (Q2)
|
$-0.30 | $-0.26 | -0.0399 | -15.34% |
|
Mar 2025 (Q1)
|
$-0.27 | $-0.26 | -0.0109 | -4.21% |
|
Dec 2024 (Q4)
|
$-0.36 | $-0.26 | -0.1019 | -39.48% |
Financial Statements
| Research and Development | $17.56M |
| Operating Income/Loss | -$26.41M |
| Income/Loss From Continuing Operations After Tax | -$25.38M |
| Income/Loss From Continuing Operations Before Tax | -$25.38M |
| Net Income/Loss | -$25.38M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$25.38M |
| Net Income/Loss Available To Common Stockholders, Basic | -$27.81M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $2.43M |
| Preferred Stock Dividends And Other Adjustments | $2.43M |
| Basic Earnings Per Share | -$1.37 |
| Diluted Earnings Per Share | -$1.37 |
| Basic Average Shares | 21,566,357 |
| Diluted Average Shares | 21,566,357 |
| Assets | $35.59M |
| Current Assets | $35.59M |
| Noncurrent Assets | $0.00 |
| Liabilities | $11.58M |
| Current Liabilities | $11.58M |
| Accounts Payable | $6.44M |
| Wages | $5.00M |
| Other Current Liabilities | $140.00K |
| Noncurrent Liabilities | $0.00 |
| Equity | $24.01M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $24.01M |
| Liabilities And Equity | $35.59M |
| Net Cash Flow From Operating Activities | -$14.50M |
| Net Cash Flow From Operating Activities, Continuing | -$14.50M |
| Net Cash Flow From Investing Activities | -$18.27M |
| Net Cash Flow From Investing Activities, Continuing | -$18.27M |
| Net Cash Flow From Financing Activities | $32.77M |
| Net Cash Flow From Financing Activities, Continuing | $32.77M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$25.38M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$25.38M |
| Other Comprehensive Income/Loss | $0.00 |